CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Hemogenyx Pharmaceuticals PLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Hemogenyx Pharmaceuticals PLC
6th Floor, 60 Gracechurch Street
LONDON, EC3V 0HR  United Kingdom Ticker: HEMOHEMO
Business Summary
Hemogenyx Pharmaceuticals plc is a preclinical-stage biotechnology company. It is engaged in the discovery, development and commercialization of a suite of products to address problems associated with the treatment of blood disorders, such as cancers and autoimmune diseases, with bone marrow or hematopoietic stem cell transplants, and with viral infections. Its products include immunotherapy product candidates for the treatment of acute myeloid leukemia (AML) and other blood malignancies and patient conditioning (the CDX bi-specific antibody and CAR-T therapy), and a cell therapy product for BM/HSC transplantation (the Hu-PHEC). Its lead product, HEMO-CAR-T, is therapy for the treatment of AML in which a patient’s own T-cells, a type of immune cell, are modified to recognize and kill the patient’s cancer cells. CBR is a versatile range of potential treatments based on the methodology of programming immune cells using a type of modifiable synthetic receptor to destroy viral pathogens.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Director GeoffreyDart
Non-Executive Chairman of the Board MarcFeldmann 4/9/2018 4/9/2018
Director PeterRedmond
7 additional Officers and Directors records available in full report.

Business Names
Business Name
HEMO
SILF

General Information
Number of Employees: 17 (As of 12/31/2023)
Outstanding Shares: 1,401,815,988 (As of 11/15/2024)
Stock Exchange: LON


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024